Cervical cancer therapy has the first tumor immunotherapy double anti -drug on the listing of double antimoted drugs in Huangpu, Guangzhou

Yangcheng Evening News reporter Hou Mengfei, correspondent Sun Xudong and Ye Ying reported: On the 9th, the world's first dual -immune examination point inhibitors bispecific antibody new drugs -Kenni (K Nili Meticuku) nationwide listing will be in Guangzhou Hosted in Huangpu District. This new drug is also China's first tumor immunotherapy dual -antidote, and the first tumor immunotherapy drug for treatment of cervical cancer.

Data show that the number of cervical cancer in China ranks second in the world, with more than 110,000 new cases in 2020. For recurrence or metastatic cervical cancer in the failure of first -line platinum chemotherapy treatment, there is currently no standard treatment. Chemotherapy is a common treatment plan for clinical practice, but the effect is limited and the toxicity is obvious.

The listing of Kaidini can be used for recurrence or metastatic cervical cancer patients that have been received in the past. According to the clinical research data, compared with the approved therapy in China, the median total survival of Kaidini's recurrence or metastatic cervical cancer patients in the whole population reached 17.51 ​​months, which was 8 to 13 months from the approved therapy for 8 to 13 months. General survival.

Not only in the field of cervical cancer, the research of Kaidani in the fields of gastric cancer, liver cancer, non -small cell lung cancer and nasopharyngeal cancer is also rapidly promoting.

This new medicine is independently developed by Kangfang Biology. The approval list also represents the Guangzhou biopharmaceutical industry cluster represented by the Huangpu District and the Guangzhou Development Zone to the international leading level. As of the end of 2021, there were more than 3,000 biomedical companies in the district, covering the full chain of research and development, production, and sales in the fields of drugs, equipment, reagents and other fields. The industrial scale exceeded 150 billion yuan, ranking the first echelon of the national biopharmaceutical industry.

- END -